GAITHERSBURG, Md., May 2, 2023
/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global
company advancing protein-based vaccines with its novel
Matrix-M™ adjuvant, today announced it will report its first
quarter 2023 financial results and operational highlights at
8:30 a.m. EDT on Tuesday, May 9,
2023. Details of the event and replay are as follows:
|
Conference call
details:
|
|
|
Date:
|
May 9, 2023
|
|
Time:
|
8:30 a.m. U.S. Eastern
Daylight Time (EDT)
|
|
Dial-in
number:
|
(877) 883-0383
(Domestic) or (412) 902-6506 (International)
|
|
Passcode:
|
3370620
|
|
Webcast:
|
ir.novavax.com/events
|
- Participants will be prompted to request to join the
Novavax, Inc. call.
- To ensure a timely connection, it is recommended that
participants join at least 10 minutes prior to the scheduled
webcast.
|
Replay
details:
|
|
|
Date:
|
Available starting at
11:30 a.m. EDT, May 9, 2023, until 11:59 p.m. U.S. EDT, May 16,
2023
|
|
Dial-in number:
|
(877) 344-7529
(Domestic) or (412) 317-0088 (International)
|
|
Passcode:
|
1969560
|
|
Webcast:
|
ir.novavax.com/events,
until August 7, 2023
|
About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes
improved health by discovering, developing and commercializing
innovative vaccines to protect against serious infectious diseases.
Novavax, a global company based in Gaithersburg, Md., U.S., offers a
differentiated vaccine platform that combines a recombinant protein
approach, innovative nanoparticle technology and Novavax's patented
Matrix-M adjuvant to enhance the immune response. Focused on the
world's most urgent health challenges, Novavax is currently
evaluating vaccines for COVID-19, influenza, and COVID-19 and
influenza combined. Please visit novavax.com and LinkedIn for
more information.
Contacts:
Investors
Erika Schultz
240-268-2022
ir@novavax.com
Media
Ali Chartan
240-720-7804
media@novavax.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/novavax-to-host-conference-call-to-discuss-first-quarter-2023-financial-results-and-operational-highlights-on-may-9-2023-301812543.html
SOURCE Novavax, Inc.